Credicorp heads into mid-September with a fresh analyst upgrade pulling in one direction and a month of quiet price erosion pulling in the other.
The most notable event this week landed this morning: JP Morgan's Yuri Fernandes upgraded Credicorp to Overweight from Neutral and raised his price target to $482 from $453. That reverses a downgrade the same analyst issued in June, when he cut to Neutral while holding the $415 target. The turnaround matters because JPM has been the most active voice on this name through 2026. The broader analyst picture is constructive — UBS raised its target to $473 in August, Morgan Stanley upgraded to Overweight back in June, and the consensus sits at buy with a mean target of $427. At $372.90, the stock trades roughly 14% below that consensus target, and $482 is now the highest published target on the Street. The one exception is Goldman Sachs, which has held Neutral throughout, last lifting its target to $374 in July — essentially right where the stock is trading now. That makes Goldman the outlier, and the gap between its view and JPM's captures the real bull-bear debate: whether Credicorp's Peruvian banking franchise deserves a re-rating or is already fairly valued after a strong run.
Valuation sits in nuanced territory. The P/E has eased to around 11.5x, down roughly half a point over the past month as the stock drifted lower. Price-to-book has similarly slipped to 2.2x. Neither multiple looks stretched for a dominant emerging-market financial, and the earnings track record is unusually clean — Credicorp ranks in the 99th percentile on EPS surprise, meaning it has almost never disappointed the consensus. The days-to-cover rank is equally healthy at the 79th percentile, while the short score of 33.7 is low and has barely moved all month, signalling no meaningful escalation in bearish conviction.
Positioning in the lending market offers nothing interesting to the bear case. Borrow availability is effectively unlimited — the lending pool is enormously deep relative to the roughly 1.16 million shares short, and fewer than 1% of those available shares have been lent out. Cost to borrow dropped sharply this week to just 0.22%, down from above 0.50% earlier in the month. Short interest itself has fallen about 6.6% over the past week and remains well under 1% of the float. This is not a stock where bears are building pressure. The options market tells a similar story: the put/call ratio of 0.89 sits modestly above its 20-day average of 0.75 but only about half a standard deviation out. There is no sign of defensive hedging or unusual directional betting in the options chain.
On the ownership side, the register has seen some movement worth noting. Capital World Investors filed a fresh Schedule 13G in August disclosing a 5.6% stake — its first filing on record for this name. BlackRock filed a 13G amendment in August showing its stake had slipped to 4.5% from 5.4%, putting it back below the 5% threshold. No 13D activist is on the register, and per the standard caveat, disclosed positions reflect the last filing date and holders dropping below 5% are not required to file again. JP Morgan Asset Management added 280,000 shares through August, which gives the upgrade filed this morning an interesting internal consistency — the asset management arm was buying while the research desk was still at Neutral. Capital Research (American Funds) also added 451,000 shares through August. Insider activity is stale beyond the 90-day window, with the last disclosed trades being discretionary sales by the CEO of Universal Banking and the CFO in May and June — modest in size and not under 10b5-1 plans, though the data is now over 100 days old.
Among closely correlated peers, NU had the roughest week, falling more than 7%, while Peruvian local-market names IFS and CREDITC1 each dropped roughly 1-2%. ITUB4 was the lone gainer, up about 0.6% on the week. BAP's 1.1% weekly decline sits in the middle of that peer range — softer than the Peruvian locals but nowhere near NU's drawdown. The next earnings event is scheduled for November 9, and given the stock's history of modest positive first-day reactions to results — up 3.8% after the August print, up 0.8% after the prior quarter — the question heading into that date will be whether the JPM upgrade reflects genuine fundamental acceleration or simply catches the Street up to where Morgan Stanley and UBS already stood.
See the live data behind this article on ORTEX.
Open BAP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
